Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Paltusotine in Healthy Volunteers
NCT03276858Phase 1Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of paltusotine in acromegaly (6 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 single ascending doses and Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 multiple ascending doses. Started Sep 2017; status: completed.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT03276858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276858.